[GNBT]
Tuesday December 2, 9:30 am ET
Results Suggest That the Company's Metformin Chewing Gum is Therapeutically Equivalent to Traditional Metformin Tablets
WORCESTER, Mass., Dec. 2, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced results from a clinical trial of MetControl(tm), the Company's proprietary Metformin chewing gum product. Results of this fully compliant ICH-GCP conducted study indicate that the MetControl Metformin chewing gum and traditional Metformin tablets are bioequivalent in respect of both the rate and the extent of systemic absorption such that MetControl and Metformin tablets are therapeutically equivalent and therefore interchangeable.
The protocol for the study is an open-label, two-treatment, two-period, randomized, crossover study comparing MetControl and immediate release Metformin tablets in healthy volunteers. The study is being conducted at West Houston Clinical Research Services in Houston, Texas. The primary objective of the study is to determine if MetControl is bioequivalent to traditional immediate release Metformin tablets. |
